Evidence map›Paper›PMID 26539170›Full record

ReviewFrontiers in microbiology2015

Extracellular vesicles from infected cells: potential for direct pathogenesis.

Angela Schwab, Shabana S Meyering, Ben Lepene, Sergey Iordanskiy, Monique L van Hoek, Ramin M Hakami, Fatah Kashanchi

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed, 153 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Towards EffectiveInternational journal of molecular sciences · 2025
    Review
  7. Article
  8. A unifying model for multiple sclerosis.Clinical and experimental medicine · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Role of Exosomes in Cardiovascular Diseases.Reviews in cardiovascular medicine · 2024
    Review
  18. Review
  19. Review
  20. Review

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Angela SchwabLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA.
Shabana S MeyeringLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA ; School of Nursing and Health Studies, Georgetown University , Washington, DC, USA.
Ben LepeneCeres Nanosciences, Inc. , Manassas, VA, USA.
Sergey IordanskiyLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA.
Monique L van HoekLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA.
Ramin M HakamiLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA.
Fatah KashanchiLaboratory of Molecular Virology, School of Systems Biology, George Mason University , Manassas, VA, USA.
George Mason University · USCeres Nanosciences · US

Funding

HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVESR01AI043894 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KASHANCHI, FATAH · 1999 to 2015
$4.4M
Structural Protein Networks ("Interactome") in HerpesvirusesR21AI070740 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ZHU, HENG · 2006 to 2007
$443k
Effect of novel cdk9 inhibitor on HIV transcriptionR21AI114490 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2014 to 2015
$428k
Nanotrap particle-based assay to quantify HIV-1 in latently-infected T cellsR21AI113140 · NIAID · GEORGE MASON UNIVERSITY · PI KASHANCHI, FATAH · 2014 to 2015
$409k
NIAID NIH HHS R01 AI043894NIAID NIH HHS R21 AI070740NIAID NIH HHS R21 AI113140NIAID NIH HHS R21 AI114490
6 · The paper itself

Abstract

Infections that result in natural or manmade spread of lethal biological agents are a concern and require national and focused preparedness. In this manuscript, as part of an early diagnostics and pathogen treatment strategy, we have focused on extracellular vesicles (EVs) that arise following infections. Although the field of biodefense does not currently have a rich resource in EVs literature, none the less, similar pathogens belonging to the more classical emerging and non-emerging diseases have been studied in their EV/exosomal contents and function. These exosomes are formed in late endosomes and released from the cell membrane in almost every cell type in vivo. These vesicles contain proteins, RNA, and lipids from the cells they originate from and function in development, signal transduction, cell survival, and transfer of infectious material. The current review focuses on how different forms of infection exploit the exosomal pathway and how exosomes can be exploited artificially to treat infection and disease and potentially also be used as a source of vaccine. Virally-infected cells can secrete viral as well as cellular proteins and RNA in exosomes, allowing viruses to cause latent infection and spread of miRNA to nearby cells prior to a subsequent infection. In addition to virally-infected host cells, bacteria, protozoa, and fungi can all release small vesicles that contain pathogen-associated molecular patterns, regulating the neighboring uninfected cells. Examples of exosomes from both virally and bacterially infected cells point toward a re-programming network of pathways in the recipient cells. Finally, many of these exosomes contain cytokines and miRNAs that in turn can effect gene expression in the recipient cells through the classical toll-like receptor and NFκB pathway. Therefore, although exosomes do not replicate as an independent entity, they however facilitate movement of infectious material through tissues and may be the cause of many pathologies seen in infected hosts.

Indexed as

bacteriaexosomeextracellular vesicleparasitepathogenprotozoavirus

Identifiers

PMID26539170
PMCPMC4611157
OpenAlexW2190237299

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.